The prognostic potential of long noncoding RNA XIST in cardiovascular diseases: a review

References

• Cao M, Luo H, Li D, Wang S, Xuan L, Sun L. Research advances on circulating long noncoding RNAs as biomarkers of cardiovascular diseases. Int J Cardiol. 2022;353:109–117. doi:10.1016/j.ijcard.2022.01.070
   PubMed Web of Science ®Google Scholar
• Lu S, Liang Q, Huang Y, Meng F, Liu J. Definition and review on a category of long non-coding RNA: atherosclerosis-associated circulating lncRNA (ASCLncRNA). PeerJ. 2020;8:e10001. doi:10.7717/peerj.10001
   PubMed Web of Science ®Google Scholar
• Poller W, Dimmeler S, Heymans S, et al. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. Eur Heart J. 2018;39(29):2704–2716. doi:10.1093/eurheartj/ehx165
   PubMed Web of Science ®Google Scholar
• Zhang P, Wu W, Chen Q, Chen M. Non-Coding RNAs and their Integrated Networks. J Integr Bioinform. 2019;16(3):20190027. doi:10.1515/jib-2019-0027
   PubMed Web of Science ®Google Scholar
• Najafi S. Circular RNAs as emerging players in cervical cancer tumorigenesis; a review to roles and biomarker potentials. Int J Biol Macromol. 2022;206:939–953. doi:10.1016/j.ijbiomac.2022.03.103
   PubMed Web of Science ®Google Scholar
• Cai CL, Jin L, Lang XL, Li BL. Long noncoding RNA XIST regulates cardiomyocyte apoptosis by targeting miR-873-5p/MCL1 axis. Eur Rev Med Pharmacol Sci. 2020;24(24):12878–12886.
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu HY, Han YL, et al. Silence of lncRNA XIST represses myocardial cell apoptosis in rats with acute myocardial infarction through regulating miR-449. Eur Rev Med Pharmacol Sci. 2019;23(19):8566–8572.
   PubMed Web of Science ®Google Scholar
• Rezaee D, Saadatpour F, Akbari N, et al. The role of microRNAs in the pathophysiology of human central nervous system: a focus on neurodegenerative diseases. Ageing Res Rev. 2023;92:102090. doi:10.1016/j.arr.2023.102090
   PubMed Web of Science ®Google Scholar
• Mehmandar-Oskuie A, Jahankhani K, Rostamlou A, Arabi S, Razavi ZS, Mardi A. Molecular landscape of LncRNAs in bladder cancer: from drug resistance to novel LncRNA-based therapeutic strategies. Biomed Pharmacother. 2023;165:115242. doi:10.1016/j.biopha.2023.115242
   PubMed Web of Science ®Google Scholar
• Kartha RV, Subramanian S. Competing endogenous RNAs (ceRNAs): new entrants to the intricacies of gene regulation. Front Genet. 2014;5:8. doi:10.3389/fgene.2014.00008
   PubMed Web of Science ®Google Scholar
• Xu J, Xu J, Liu X, Jiang J. The role of lncRNA-mediated ceRNA regulatory networks in pancreatic cancer. Cell Death Discovery. 2022;8(1):287. doi:10.1038/s41420-022-01061-x
   PubMed Web of Science ®Google Scholar
• Wang W, Min L, Qiu X, et al. Biological function of long non-coding RNA (LncRNA) Xist. Front Cell Dev Biol. 2021;9:645647. doi:10.3389/fcell.2021.645647
   PubMed Web of Science ®Google Scholar
• Lekka E, Hall J. Noncoding RNAs in disease. FEBS Lett. 2018;592(17):2884–2900. doi:10.1002/1873-3468.13182
   PubMed Web of Science ®Google Scholar
• Yang J, Qi M, Fei X, Wang X, Wang K. Long non-coding RNA XIST: a novel oncogene in multiple cancers. Mol Med. 2021;27(1):159. doi:10.1186/s10020-021-00421-0
   PubMed Web of Science ®Google Scholar
• Razeghian-Jahromi I, Karimi Akhormeh A, Zibaeenezhad MJ. The role of ANRIL in atherosclerosis. DisMarkers. 2022;2022:8859677. doi:10.1155/2022/8859677
   Google Scholar
• Yan Y, Song D, Song X, Song C. The role of lncRNA MALAT1 in cardiovascular disease. IUBMB Life. 2020;72(3):334–342. doi:10.1002/iub.2210
   PubMed Web of Science ®Google Scholar
• Siniscalchi C, Di Palo A, Russo A, Potenza N. The lncRNAs at X chromosome inactivation center: not just a matter of sex dosage compensation. Int J Mol Sci. 2022;23(2):611. doi:10.3390/ijms23020611
   PubMed Web of Science ®Google Scholar
• Zampetaki A, Albrecht A, Steinhofel K. Long Non-coding RNA Structure and Function: is there a link? Front Physiol. 2018;9:1201. doi:10.3389/fphys.2018.01201
   PubMed Web of Science ®Google Scholar
• Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006;47(Suppl. 8):C7–12. doi:10.1016/j.jacc.2005.09.068
   PubMed Web of Science ®Google Scholar
• Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med. 2014;5(8):927–946.
   PubMedGoogle Scholar
• Bok JS, Byun SH, Park BW, et al. The Role of Human Umbilical Vein Endothelial Cells in Osteogenic Differentiation of Dental Follicle-Derived Stem Cells in in vitro co-cultures. Int J Med Sci. 2018;15(11):1160–1170. doi:10.7150/ijms.27318
   PubMed Web of Science ®Google Scholar
• Zhang R, Qin Y, Zhu G, Li Y, Xue J. Low serum miR-320b expression as a novel indicator of carotid atherosclerosis. J Clin Neurosci. 2016;33:252–258. doi:10.1016/j.jocn.2016.03.034
   PubMed Web of Science ®Google Scholar
• Xu X, Ma C, Liu C, Duan Z, Zhang L. Knockdown of long noncoding RNA XIST alleviates oxidative low-density lipoprotein-mediated endothelial cells injury through modulation of miR-320/NOD2 axis. Biochem Biophys Res Commun. 2018;503(2):586–592. doi:10.1016/j.bbrc.2018.06.042
   PubMed Web of Science ®Google Scholar
• Johansson ME, Zhang XY, Edfeldt K, et al. Innate immune receptor NOD2 promotes vascular inflammation and formation of lipid-rich necrotic cores in hypercholesterolemic mice. Eur J Immunol. 2014;44(10):3081–3092. doi:10.1002/eji.201444755
   PubMed Web of Science ®Google Scholar
• Liu HQ, Zhang XY, Edfeldt K, et al. NOD2-mediated innate immune signaling regulates the eicosanoids in atherosclerosis. Arterioscler Thromb Vasc Biol. 2013;33(9):2193–2201. doi:10.1161/ATVBAHA.113.301715
   PubMed Web of Science ®Google Scholar
• Vlacil AK, Schuett J, Ruppert V, et al. Deficiency of nucleotide-binding oligomerization domain-containing proteins (NOD) 1 and 2 reduces atherosclerosis. Basic Res Cardiol. 2020;115(4):47. doi:10.1007/s00395-020-0806-2
   PubMed Web of Science ®Google Scholar
• Moriya J. Critical roles of inflammation in atherosclerosis. J Cardiol. 2019;73(1):22–27. doi:10.1016/j.jjcc.2018.05.010
   PubMed Web of Science ®Google Scholar
• Lu G, Tian P, Zhu Y, Zuo X, Li X. LncRNA XIST knockdown ameliorates oxidative low-density lipoprotein-induced endothelial cells injury by targeting miR-204-5p/TLR4. J Biosci. 2020;45:52. doi:10.1007/s12038-020-0022-0
   PubMed Web of Science ®Google Scholar
• Zhao J, Cui L, Sun J, et al. Notoginsenoside R1 alleviates oxidized low-density lipoprotein-induced apoptosis, inflammatory response, and oxidative stress in HUVECS through modulation of XIST/miR-221-3p/TRAF6 axis. Cell Signal. 2020;76:109781. doi:10.1016/j.cellsig.2020.109781
   PubMed Web of Science ®Google Scholar
• Zirlik A, Bavendiek U, Libby P, et al. TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27(5):1101–1107. doi:10.1161/ATVBAHA.107.140566
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Genco CA. Directing TRAF-ic: cell-specific TRAF6 signaling in chronic inflammation and atherosclerosis. Circulation. 2012;126(14):1678–1680. doi:10.1161/CIRCULATIONAHA.112.134379
   PubMed Web of Science ®Google Scholar
• Wang W, Li H, Shi Y, et al. Targeted intervention of natural medicinal active ingredients and traditional Chinese medicine on epigenetic modification: possible strategies for prevention and treatment of atherosclerosis. Phytomedicine. 2024;122:155139. doi:10.1016/j.phymed.2023.155139
   PubMed Web of Science ®Google Scholar
• Zhuang X, Li R, Maimaitijiang A, et al. miR-221-3p inhibits oxidized low-density lipoprotein induced oxidative stress and apoptosis via targeting a disintegrin and metalloprotease-22. J Cell Biochem. 2019;120(4):6304–6314. doi:10.1002/jcb.27917
   PubMed Web of Science ®Google Scholar
• Gao H, Guo Z. LncRNA XIST regulates atherosclerosis progression in ox-LDL-induced HUVECs. Open Med (Wars). 2021;16(1):117–127. doi:10.1515/med-2021-0200
   PubMedGoogle Scholar
• Consuegra-Sanchez L, Fredericks S, Kaski JC. Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk. Atherosclerosis. 2009;203(2):346–352. doi:10.1016/j.atherosclerosis.2008.07.042
   PubMed Web of Science ®Google Scholar
• Harrington SC, Simari RD, Conover CA. Genetic deletion of pregnancy-associated plasma protein-A is associated with resistance to atherosclerotic lesion development in apolipoprotein E-deficient mice challenged with a high-fat diet. Circ Res. 2007;100(12):1696–1702. doi:10.1161/CIRCRESAHA.106.146183
   PubMed Web of Science ®Google Scholar
• Yu XH, He LH, Gao JH, Zhang DW, Zheng XL, Tang CK. Pregnancy-associated plasma protein-A in atherosclerosis: molecular marker, mechanistic insight, and therapeutic target. Atherosclerosis. 2018;278:250–258. doi:10.1016/j.atherosclerosis.2018.10.004
   PubMed Web of Science ®Google Scholar
• Peng K, Jiang P, Du Y, et al. Oxidized low-density lipoprotein accelerates the injury of endothelial cells via circ-USP36/miR-98-5p/VCAM1 axis. IUBMB Life. 2021;73(1):177–187. doi:10.1002/iub.2419
   PubMed Web of Science ®Google Scholar
• Zheng Z, Zhang G, Liang X, Li T. LncRNA OIP5-AS1 facilitates ox-LDL-induced endothelial cell injury through the miR-98-5p/HMGB1 axis. Mol Cell Biochem. 2021;476(1):443–455. doi:10.1007/s11010-020-03921-5
   PubMed Web of Science ®Google Scholar
• Hu WN, Duan ZY, Wang Q, Zhou DH. The suppression of ox-LDL-induced inflammatory response and apoptosis of HUVEC by lncRNA XIAT knockdown via regulating miR-30c-5p/PTEN axis. Eur Rev Med Pharmacol Sci. 2019;23(17):7628–7638.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li SF, Chen H, Song JX. MiR-106b-5p inhibits tumor necrosis factor-α-induced apoptosis by targeting phosphatase and tensin homolog deleted on chromosome 10 in vascular endothelial cells. Chin Med J (Engl). 2016;129(12):1406–1412. doi:10.4103/0366-6999.183414
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang L, Xu J, Kong X, Zou L. Up-regulated miR-106b inhibits ox-LDL-induced endothelial cell apoptosis in atherosclerosis. Braz J Med Biol Res. 2020;53(3):e8960. doi:10.1590/1414-431x20198960
   PubMed Web of Science ®Google Scholar
• Guo JT, Wang L, Yu HB. Knockdown of NEAT1 mitigates ox-LDL-induced injury in human umbilical vein endothelial cells via miR-30c-5p/TCF7 axis. Eur Rev Med Pharmacol Sci. 2020;24(18):9633–9644.
   PubMed Web of Science ®Google Scholar
• Li G, Zong W, Liu L, Wu J, Pang J. Knockdown of long non-coding RNA plasmacytoma variant translocation 1 relieves ox-LDL-induced endothelial cell injury through regulating microRNA-30c-5p in atherosclerosis. Bioengineered. 2022;13(2):2791–2802. doi:10.1080/21655979.2021.2019878
   PubMed Web of Science ®Google Scholar
• Ceolotto G, Giannella A, Albiero M, et al. miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways. Cardiovasc Res. 2017;113(13):1627–1638. doi:10.1093/cvr/cvx157
   PubMed Web of Science ®Google Scholar
• Vilahur G. Relevance of low miR-30c-5p levels in atherogenesis: a promising predictive biomarker and potential therapeutic target. Cardiovasc Res. 2017;113(13):1536–1537. doi:10.1093/cvr/cvx194
   PubMed Web of Science ®Google Scholar
• Chen Z, Xue Q, Cao L, et al. Toll-like receptor 4 mediated oxidized low-density lipoprotein-induced foam cell formation in vascular smooth Muscle cells via Src and Sirt1/3 pathway. Mediators Inflamm. 2021;2021:6639252. doi:10.1155/2021/6639252
   PubMed Web of Science ®Google Scholar
• Curtiss LK, Tobias PS. Emerging role of Toll-like receptors in atherosclerosis. J Lipid Res. 2009;50(Suppl.):S340–S345. doi:10.1194/jlr.R800056-JLR200
   PubMedGoogle Scholar
• Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res. 2016;118(4):692–702. doi:10.1161/CIRCRESAHA.115.306361
   PubMed Web of Science ®Google Scholar
• Li H, Sun B. Toll-like receptor 4 in atherosclerosis. J Cell Mol Med. 2007;11(1):88–95. doi:10.1111/j.1582-4934.2007.00011.x
   PubMed Web of Science ®Google Scholar
• Yang K, Zhang XJ, Cao LJ, et al. Toll-like receptor 4 mediates inflammatory cytokine secretion in smooth muscle cells induced by oxidized low-density lipoprotein. PLOS ONE. 2014;9(4):e95935. doi:10.1371/journal.pone.0095935
   PubMed Web of Science ®Google Scholar
• Stoll LL, Denning GM, Li WG, et al. Regulation of endotoxin-induced proinflammatory activation in human coronary artery cells: expression of functional membrane-bound CD14 by human coronary artery smooth muscle cells. J Immunol. 2004;173(2):1336–1343. doi:10.4049/jimmunol.173.2.1336
   PubMed Web of Science ®Google Scholar
• Yang K, Xue Y, Gao X. LncRNA XIST Promotes Atherosclerosis by Regulating miR-599/TLR4 Axis. Inflammation.2021;44(3):965–973. doi:10.1007/s10753-020-01391-x
   PubMed Web of Science ®Google Scholar
• Zhang Y, Tang Y, Yan J. LncRNA-XIST Promotes Proliferation and Migration in ox-LDL Stimulated Vascular Smooth Muscle Cells through miR-539-5p/SPP1 Axis. Oxid Med Cell Longev. 2022;2022:9911982. doi:10.1155/2022/9911982
   PubMed Web of Science ®Google Scholar
• Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993;92(4):1686–1696. doi:10.1172/JCI116755
   PubMed Web of Science ®Google Scholar
• Fontaine M, Herkenne S, Ek O, et al. Extracellular vesicles mediate communication between endothelial and vascular smooth muscle cells. Int J Mol Sci. 2021;23(1):331. doi:10.3390/ijms23010331
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Orekhov AN, Bobryshev YV. Vascular smooth muscle cell in atherosclerosis. Acta Physiol (Oxf). 2015;214(1):33–50. doi:10.1111/apha.12466
   PubMed Web of Science ®Google Scholar
• Zhu D, Mackenzie NC, Shanahan CM, Shroff RC, Farquharson C, MacRae VE. BMP-9 regulates the osteoblastic differentiation and calcification of vascular smooth muscle cells through an ALK1 mediated pathway. J Cell Mol Med. 2015;19(1):165–174. doi:10.1111/jcmm.12373
   PubMed Web of Science ®Google Scholar
• Mo L, Jiang HB, Tian GR, Lu GJ. The proliferation and migration of atherosclerosis-related HVSMCs were inhibited by downregulation of lncRNA XIST via regulation of the miR-761/BMP9 axis. Kaohsiung J Med Sci. 2022;38(1):18–29. doi:10.1002/kjm2.12456
   PubMed Web of Science ®Google Scholar
• Mitrofan CG, Appleby SL, Nash GB, et al. Bone morphogenetic protein 9 (BMP9) and BMP10 enhance tumor necrosis factor-α-induced monocyte recruitment to the vascular endothelium mainly via activin receptor-like kinase 2. J Biol Chem. 2017;292(33):13714–13726. doi:10.1074/jbc.M117.778506
   PubMed Web of Science ®Google Scholar
• Del Re DP, Amgalan D, Linkermann A, Liu Q, Kitsis RN. Fundamental mechanisms of regulated cell death and implications for heart disease. Physiol Rev. 2019;99(4):1765–1817. doi:10.1152/physrev.00022.2018
   PubMed Web of Science ®Google Scholar
• Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol. 2012;298:229–317. doi:10.1016/B978-0-12-394309-5.00006-7
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang Y, Ding N, et al. Inhibition of lncRNA XIST Improves Myocardial I/R Injury by Targeting miR-133a through Inhibition of Autophagy and Regulation of SOCS2. Mol Ther Nucleic Acids. 2019;18:764–773. doi:10.1016/j.omtn.2019.10.004
   PubMedGoogle Scholar
• Liang D, Jin Y, Lin M, Xia X, Chen X, Huang A. Down-regulation of Xist and Mir-7a-5p improves LPS-induced myocardial injury. Int J Med Sci. 2020;17(16):2570–2577. doi:10.7150/ijms.45408
   PubMed Web of Science ®Google Scholar
• Lin B, Xu J, Wang F, Wang J, Zhao H, Feng D. LncRNA XIST promotes myocardial infarction by regulating FOS through targeting miR-101a-3p. Aging (Albany NY). 2020;12(8):7232–7247. doi:10.18632/aging.103072
   PubMedGoogle Scholar
• Wang Y, Liu Y, Fei A, Yu Z. LncRNA XIST facilitates hypoxia-induced myocardial cell injury through targeting miR-191-5p/TRAF3 axis. Mol Cell Biochem. 2022;477(6):1697–1707. doi:10.1007/s11010-022-04385-5
   PubMed Web of Science ®Google Scholar
• Xiao X, He Z, Tong S, et al. lncRNA XIST knockdown suppresses hypoxia/reoxygenation (H/R)-induced apoptosis of H9C2 cells by regulating miR-545-3p/G3BP2. IUBMB Life. 2021;73(9):1103–1114. doi:10.1002/iub.2512
   PubMed Web of Science ®Google Scholar
• Zhou J, Li D, Yang BP, Cui WJ. LncRNA XIST inhibits hypoxia-induced cardiomyocyte apoptosis via mediating miR-150-5p/Bax in acute myocardial infarction. Eur Rev Med Pharmacol Sci. 2020;24(3):1357–1366.
   PubMed Web of Science ®Google Scholar
• Zhou T, Qin G, Yang L, Xiang D, Li S. LncRNA XIST regulates myocardial infarction by targeting miR-130a-3p. J Cell Physiol. 2019;234(6):8659–8667. doi:10.1002/jcp.26327
   PubMed Web of Science ®Google Scholar
• Peña-Blanco A, García-Sáez AJ. Bax, Bak and beyond - mitochondrial performance in apoptosis. FEBS J. 2018;285(3):416–431. doi:10.1111/febs.14186
   PubMed Web of Science ®Google Scholar
• Wang K, Liu F, Liu CY, et al. The long noncoding RNA NRF regulates programmed necrosis and myocardial injury during ischemia and reperfusion by targeting miR-873. Cell Death Differ. 2016;23(8):1394–1405. doi:10.1038/cdd.2016.28
   PubMed Web of Science ®Google Scholar
• Liu Z, Ye P, Wang S, et al. MicroRNA-150 protects the heart from injury by inhibiting monocyte accumulation in a mouse model of acute myocardial infarction. Circ Cardiovasc Genet. 2015;8(1):11–20. doi:10.1161/CIRCGENETICS.114.000598
   PubMedGoogle Scholar
• Tang Y, Wang Y, Park KM, et al. MicroRNA-150 protects the mouse heart from ischaemic injury by regulating cell death. Cardiovasc. Res. 2015;106(3):387–397. doi:10.1093/cvr/cvv121
   PubMed Web of Science ®Google Scholar
• Ren K, Li B, Jiang L, et al. circ_0023461 silencing protects cardiomyocytes from hypoxia-induced dysfunction through targeting miR-370-3p/PDE4D signaling. Oxid Med Cell Longev. 2021;2021:8379962. doi:10.1155/2021/8379962
   PubMed Web of Science ®Google Scholar
• Pan X, He Y, Chen Z, Yan G, Ma G. Circulating miR-130 is a potential bio signature for early prognosis of acute myocardial infarction. J Thorac Dis. 2020;12(12):7320–7325. doi:10.21037/jtd-20-3207
   PubMed Web of Science ®Google Scholar
• Chu X, Wang Y, Pang L, Huang J, Sun X, Chen X. miR-130 aggravates acute myocardial infarction-induced myocardial injury by targeting PPAR-γ. J Cell Biochem. 2018;119(9):7235–7244. doi:10.1002/jcb.26903
   PubMed Web of Science ®Google Scholar
• Du M, Shan J, Feng A, Schmull S, Gu J, Xue S. Oestrogen receptor β activation protects against myocardial infarction via notch1 signalling. Cardiovasc Drugs Ther. 2020;34(2):165–178. doi:10.1007/s10557-020-06949-3
   PubMed Web of Science ®Google Scholar
• Yang H, Sun W, Quan N, et al. Cardioprotective actions of Notch1 against myocardial infarction via LKB1-dependent AMPK signaling pathway. Biochem Pharmacol. 2016;108:47–57. doi:10.1016/j.bcp.2016.03.019
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang X, Zhang Y. Astragaloside attenuates myocardial injury in a rat model of acute myocardial infarction by upregulating hypoxia inducible factor-1α and Notch1/Jagged1 signaling. Mol Med Rep. 2017;15(6):4015–4020. doi:10.3892/mmr.2017.6522
   PubMed Web of Science ®Google Scholar
• Cheng S, Zhang X, Feng Q, et al. Astragaloside IV exerts angiogenesis and cardioprotection after myocardial infarction via regulating PTEN/PI3K/Akt signaling pathway. Life Sci. 2019;227:82–93. doi:10.1016/j.lfs.2019.04.040
   PubMed Web of Science ®Google Scholar
• Pei H, Yu Q, Xue Q, et al. Notch1 cardioprotection in myocardial ischemia/reperfusion involves reduction of oxidative/nitrative stress. Basic Res Cardiol. 2013;108(5):373. doi:10.1007/s00395-013-0373-x
   PubMed Web of Science ®Google Scholar
• Peng H, Luo Y, Ying Y. lncRNA XIST attenuates hypoxia-induced H9c2 cardiomyocyte injury by targeting the miR-122-5p/FOXP2 axis. Mol Cell Probes. 2020;50:101500. doi:10.1016/j.mcp.2019.101500
   PubMed Web of Science ®Google Scholar
• Xie J. Long Noncoding RNA XIST Regulates Myocardial Infarction via miR-486-5p/SIRT1 Axis. Appl Biochem Biotechnol. 2023;195(2):725–734. doi:10.1007/s12010-022-04165-3
   PubMed Web of Science ®Google Scholar
• Sun X, Han Y, Dong C, et al. Daming capsule protects against myocardial infarction by promoting mitophagy via the SIRT1/AMPK signaling pathway. Biomed Pharmacother. 2022;151:113162. doi:10.1016/j.biopha.2022.113162
   PubMed Web of Science ®Google Scholar
• Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014;71(4):549–574. doi:10.1007/s00018-013-1349-6
   PubMed Web of Science ®Google Scholar
• Zhang H, Ma J, Liu F, Zhang J. Long non-coding RNA XIST promotes the proliferation of cardiac fibroblasts and the accumulation of extracellular matrix by sponging microRNA-155-5p. Exp Ther Med. 2021;21(5):477. doi:10.3892/etm.2021.9908
   PubMed Web of Science ®Google Scholar
• Eissa MG, Artlett CM. The microRNA miR-155 is essential in fibrosis. Noncoding RNA. 2019;5(1):23. doi:10.3390/ncrna5010023
   PubMed Web of Science ®Google Scholar
• Li Y, Duan JZ, He Q, Wang CQ. miR-155 modulates high glucose-induced cardiac fibrosis via the Nrf2/HO-1 signaling pathway. Mol Med Rep. 2020;22(5):4003–4016. doi:10.3892/mmr.2020.11495
   PubMed Web of Science ®Google Scholar
• Wei Y, Yan X, Yan L, et al. Inhibition of microRNA-155 ameliorates cardiac fibrosis in the process of angiotensin II-induced cardiac remodeling. Mol Med Rep. 2017;16(5):7287–7296. doi:10.3892/mmr.2017.7584
   PubMed Web of Science ®Google Scholar
• Wang F, Fan K, Zhao Y, Xie ML. Apigenin attenuates TGF-β1-stimulated cardiac fibroblast differentiation and extracellular matrix production by targeting miR-155-5p/c-Ski/Smad pathway. J Ethnopharmacol. 2021;265:113195. doi:10.1016/j.jep.2020.113195
   PubMed Web of Science ®Google Scholar
• Wang F, Zhang J, Niu G, et al. Apigenin inhibits isoproterenol-induced myocardial fibrosis and Smad pathway in mice by regulating oxidative stress and miR-122-5p/155-5p expressions. Drug Dev Res. 2022;83(4):1003–1015. doi:10.1002/ddr.21928
   PubMed Web of Science ®Google Scholar
• Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol. 2018;15(7):387–407. doi:10.1038/s41569-018-0007-y
   PubMed Web of Science ®Google Scholar
• Xiao L, Gu Y, Sun Y,et al. The long noncoding RNA XIST regulates cardiac hypertrophy by targeting miR-101. J Cell Physiol. 2019;234(8):13680–13692. doi:10.1002/jcp.28047
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu X, Chen L, et al. The long noncoding RNA XIST protects cardiomyocyte hypertrophy by targeting miR-330-3p. Biochem Biophys Res Commun. 2018;505(3):807–815. doi:10.1016/j.bbrc.2018.09.135
   PubMed Web of Science ®Google Scholar
• Gardner DG. Natriuretic peptides: markers or modulators of cardiac hypertrophy? Trends Endocrinol Metab. 2003;14(9):411–416. doi:10.1016/S1043-2760(03)00113-9
   PubMed Web of Science ®Google Scholar
• Higashikuni Y, Tanaka K, Kato M, et al. Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1β upregulation via nuclear factor κB activation. J Am Heart Assoc. 2013;2(6):e000267. doi:10.1161/JAHA.113.000267
   PubMed Web of Science ®Google Scholar
• Trentin-Sonoda M, da Silva RC, Kmit FV, et al. Knockout of Toll-Like Receptors 2 and 4 Prevents Renal Ischemia-Reperfusion-Induced Cardiac Hypertrophy in Mice. PLOS ONE. 2015;10(10):e0139350. doi:10.1371/journal.pone.0139350
   PubMed Web of Science ®Google Scholar
• Parker TG, Marks A, Tsoporis JN. Induction of S100b in myocardium: an intrinsic inhibitor of cardiac hypertrophy. Can J Appl Physiol. 1998;23(4):377–389. doi:10.1139/h98-022
   PubMedGoogle Scholar
• Tsoporis JN, Marks A, Kahn HJ, et al. S100beta inhibits alpha1-adrenergic induction of the hypertrophic phenotype in cardiac myocytes. J Biol Chem. 1997;272(50):31915–31921. doi:10.1074/jbc.272.50.31915
   PubMed Web of Science ®Google Scholar
• Tsoporis JN, Marks A, Kahn HJ, et al. Inhibition of norepinephrine-induced cardiac hypertrophy in s100beta transgenic mice. J Clin Invest. 1998;102(8):1609–1616. doi:10.1172/JCI3077
   PubMed Web of Science ®Google Scholar
• Luo Y, Chen J, Chen Y, et al. Qishen Yiqi dropping pills improve isoproterenol-induced cardiomyocyte hypertrophy by regulating X-inactive specific transcript (XIST) expression in rats. J Thorac Dis. 2022;14(6):2213–2223. doi:10.21037/jtd-22-606
   PubMed Web of Science ®Google Scholar
• Lu H, Du W, Ren L, et al. Vascular smooth muscle cells in aortic aneurysm: from genetics to mechanisms. J Am Heart Assoc. 2021;10(24):e023601. doi:10.1161/JAHA.121.023601
   PubMed Web of Science ®Google Scholar
• Gao J, Cao H, Hu G, et al. The mechanism and therapy of aortic aneurysms. Signal Transduct Target Ther. 2023;8(1):55. doi:10.1038/s41392-023-01325-7
   PubMed Web of Science ®Google Scholar
• Zou L, Xia PF, Chen L, Hou YY. XIST knockdown suppresses vascular smooth muscle cell proliferation and induces apoptosis by regulating miR-1264/WNT5A/β-catenin signaling in aneurysm. BiosciRep. 2021;41(3):BSR20201810. doi:10.1042/BSR20201810
   Web of Science ®Google Scholar
• Bennett MR, Evan GI, Newby AC. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-gamma, heparin, and cyclic nucleotide analogues and induces apoptosis. Circ Res. 1994;74(3):525–536. doi:10.1161/01.RES.74.3.525
   PubMed Web of Science ®Google Scholar
• Lyon C, Mill C, Tsaousi A, Williams H, George S. Regulation of VSMC behavior by the cadherin-catenin complex. Front Biosci (Landmark Ed). 2011;16(2):644–657. doi:10.2741/3711
   PubMedGoogle Scholar
• Zhang L, Cheng H, Yue Y, Li S, Zhang D, He R. H19 knockdown suppresses proliferation and induces apoptosis by regulating miR-148b/WNT/β-catenin in ox-LDL -stimulated vascular smooth muscle cells. J Biomed Sci. 2018;25(1):11. doi:10.1186/s12929-018-0418-4
   PubMed Web of Science ®Google Scholar
• Zhang D, Lu D, Xu R, Zhai S, Zhang K. Inhibition of XIST attenuates abdominal aortic aneurysm in mice by regulating apoptosis of vascular smooth muscle cells through miR-762/MAP2K4 axis. Microvasc Res. 2022;140:104299. doi:10.1016/j.mvr.2021.104299
   PubMed Web of Science ®Google Scholar
• Whitmarsh AJ, Davis RJ. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene. 2007;26(22):3172–3184. doi:10.1038/sj.onc.1210410
   PubMed Web of Science ®Google Scholar
• Li C, Wang T, Zhang C, Xuan J, Su C, Wang Y. Quercetin attenuates cardiomyocyte apoptosis via inhibition of JNK and p38 mitogen-activated protein kinase signaling pathways. Gene. 2016;577(2):275–280. doi:10.1016/j.gene.2015.12.012
   PubMed Web of Science ®Google Scholar
• Wang L, Cheng X, Li H, et al. Quercetin reduces oxidative stress and inhibits activation of c-Jun N-terminal kinase/activator protein-1 signaling in an experimental mouse model of abdominal aortic aneurysm. Mol Med Rep. 2014;9(2):435–442. doi:10.3892/mmr.2013.1846
   PubMed Web of Science ®Google Scholar
• Wang L, Wang B, Li H, et al. Quercetin, a flavonoid with anti-inflammatory activity, suppresses the development of abdominal aortic aneurysms in mice. Eur J Pharmacol. 2012;690(1–3):133–141. doi:10.1016/j.ejphar.2012.06.018
   PubMed Web of Science ®Google Scholar
• Liang K, Cui M, Fu X, et al. LncRNA Xist induces arterial smooth muscle cell apoptosis in thoracic aortic aneurysm through miR-29b-3p/Eln pathway. Biomed Pharmacother. 2021;137:111163. doi:10.1016/j.biopha.2020.111163
   PubMed Web of Science ®Google Scholar
• Jana S, Hu M, Shen M, Kassiri Z. Extracellular matrix, regional heterogeneity of the aorta, and aortic aneurysm. Exp Mol Med. 2019;51(12):1–15. doi:10.1038/s12276-019-0286-3
   PubMedGoogle Scholar
• Nienaber CA, Clough RE, Sakalihasan N, et al. Aortic dissection. Nat Rev Dis Primers. 2016;2:16071. doi:10.1038/nrdp.2016.71
   PubMed Web of Science ®Google Scholar
• Rombouts KB, van Merrienboer TAR, Ket JCF, Bogunovic N, van der Velden J, Yeung KK. The role of vascular smooth muscle cells in the development of aortic aneurysms and dissections. Eur J Clin Invest. 2022;52(4):e13697. doi:10.1111/eci.13697
   PubMed Web of Science ®Google Scholar
• Wei R, Feng Y. Noncoding RNA in the regulation of acute aortic dissection: from profile to mechanism. Cardiovasc Ther. 2022;2022:2371401. doi:10.1155/2022/2371401
   PubMed Web of Science ®Google Scholar
• Sun J, Chen G, Jing Y, et al. LncRNA expression profile of human thoracic aortic dissection by high-throughput sequencing. Cell Physiol Biochem. 2018;46(3):1027–1041. doi:10.1159/000488834
   PubMedGoogle Scholar
• Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst). 2016;42:63–71. doi:10.1016/j.dnarep.2016.04.008
   PubMed Web of Science ®Google Scholar
• Zhang X, Wu H, Mai C, Qi Y. Long Noncoding RNA XIST/miR-17/PTEN axis modulates the proliferation and apoptosis of vascular smooth muscle cells to affect stanford type A aortic dissection. J Cardiovasc Pharmacol. 2020;76(1):53–62. doi:10.1097/FJC.0000000000000835
   PubMed Web of Science ®Google Scholar
• Liang T, Gao F, Chen J. Role of PTEN-less in cardiac injury, hypertrophy and regeneration. Cell Regen. 2021;10(1):25. doi:10.1186/s13619-021-00087-3
   PubMedGoogle Scholar
• Oudit GY, Kassiri Z, Zhou J, et al. Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress. Cardiovasc Res. 2008;78(3):505–514. doi:10.1093/cvr/cvn041
   PubMed Web of Science ®Google Scholar
• Lai Y, Li J, Zhong L, et al. The pseudogene PTENP1 regulates smooth muscle cells as a competing endogenous RNA. Clin Sci (Lond). 2019;133(13):1439–1455. doi:10.1042/CS20190156
   PubMed Web of Science ®Google Scholar
• Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60(22):2263–2270. doi:10.1016/j.jacc.2012.04.063
   PubMed Web of Science ®Google Scholar
• Yao C, Veleva T, Scott L Jr, et al.. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circulation. 2018;138(20):2227–2242. doi:10.1161/CIRCULATIONAHA.118.035202
   PubMed Web of Science ®Google Scholar
• Zhaolin Z, Guohua L, Shiyuan W, Zuo W. Role of pyroptosis in cardiovascular disease. Cell Prolif. 2019;52(2):e12563. doi:10.1111/cpr.12563
   PubMed Web of Science ®Google Scholar
• Yan B, Liu T, Yao C, Liu X, Du Q, Pan L. LncRNA XIST shuttled by adipose tissue-derived mesenchymal stem cell-derived extracellular vesicles suppresses myocardial pyroptosis in atrial fibrillation by disrupting miR-214-3p-mediated Arl2 inhibition. Lab Invest. 2021;101(11):1427–1438. doi:10.1038/s41374-021-00635-0
   PubMed Web of Science ®Google Scholar
• Wang Y, Jin P, Liu J, Xie X. Exosomal microRNA-122 mediates obesity-related cardiomyopathy through suppressing mitochondrial ADP-ribosylation factor-like 2. Clin Sci (Lond). 2019;133(17):1871–1881. doi:10.1042/CS20190558
   PubMed Web of Science ®Google Scholar
• Wang X, Li XL, Qin LJ. The lncRNA XIST/miR-150-5p/c-Fos axis regulates sepsis-induced myocardial injury via TXNIP-modulated pyroptosis. Lab Invest. 2021;101(9):1118–1129. doi:10.1038/s41374-021-00607-4
   PubMed Web of Science ®Google Scholar
• Xu J, Wang Q, Song YF, et al. Long noncoding RNA X-inactive specific transcript regulates NLR family pyrin domain containing 3/caspase-1-mediated pyroptosis in diabetic nephropathy. World J Diabetes. 2022;13(4):358–375. doi:10.4239/wjd.v13.i4.358
   PubMed Web of Science ®Google Scholar
• Han Y, Jin G, Pan M, et al. Integrated bioinformatics and validation of lncRNA-mediated ceRNA network in myocardial ischemia/reperfusion injury. J Immunol Res. 2022;2022:7260801. doi:10.1155/2022/7260801
   PubMed Web of Science ®Google Scholar
• Xu J, Li J, Xu X, et al. IncRNA XIST promotes cardiac fibrosis in mice with diabetic nephropathy via sponging miR-106a-5p to target RUNX1. Crit Rev Eukaryot Gene Expr. 2023;33(2):55–66. doi:10.1615/CritRevEukaryotGeneExpr.2022044404
   PubMed Web of Science ®Google Scholar